| Literature DB >> 30538509 |
Yousry Esam-Eldin Abo-Amer1, Sherief Abd-Elsalam2, Hazim Eldosoky3, Amira K ELShenawy4, Shereen Awny5, Waleed Elagawy6, Mohamed El Abgeegy6, Heba Fadl Elsergany6, Heba Elashry2, Manal Saad Negm5.
Abstract
BACKGROUND AND AIMS: Egypt is considered to have the highest rate of hepatitis C virus (HCV) prevalence worldwide. However, HCV prevalence is currently declining due to the improvement of health education programs, improved environmental sanitation, and the introduction of novel treatment regimens. The aim of this work was to determine the HCV seroprevalence among Menoufia University students.Entities:
Keywords: DAA; Egypt; HCV; Menoufia University; direct acting antiviral; eradication; hepatitis C virus; infection; prevalence; students; treatment
Year: 2018 PMID: 30538509 PMCID: PMC6254504 DOI: 10.2147/IDR.S183462
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Sociodemographic features of the students
| Category | Students (N=48,972), n (%) | |
|---|---|---|
| Gender | Male | 21,371 (43.8) |
| Female | 27,421 (56.2) | |
| Age (years) | Mean | 18±0.056 |
| Place of origin | Upper Egypt | 1,448 (3) |
| Lower Egypt | 47,344 (97) | |
| Place of residence | Rural | 20,057 (41.1) |
| Urban | 28,735 (58.9) | |
| Family history of HCV | Positive | 10,868 (22.3) |
| Negative | 37,924 (77.7) | |
Abbreviation: HCV, hepatitis C virus.
Seroprevalence of anti-HCV among the students and HCV RNA positivity (among the students than among the anti-HCV-positive students)
| Studied subjects | Positive, n (%) | Negative, n (%) | |
|---|---|---|---|
| Students (n=48,792) | 498 (1) | 48,294 (99) | |
| Gender | |||
| Males | 194 (0.9) | 21,177 (99.1) | 0.029 |
| Females | 304 (1.1) | 27,117 (98.9) | |
| Students (n=48,792) | 355 (0.7) | 48,437 (99.3) | |
| Gender | |||
| Males | 147(0.7) | 21,224 (99.3) | 0.362 |
| Females | 208(0.8) | 27,213 (99.2) | |
| Anti-HCV-positive students (498) | 355 (71.3) | 143 (28.7) | |
| Gender | |||
| Males | 147 (75.8) | 47 (24.2) | 0.077 |
| Females | 93 (31.6) | 208 (68.4) | |
Abbreviation: HCV, hepatitis C virus.
Possible sources of HCV infection among the students
| Risk factors | Anti-HCV | |||
|---|---|---|---|---|
| Negative (n=48,294), n (%) | Positive (n=498), n (%) | Total (n=48,792), n (%) | ||
| Blood transfusion | ||||
| Yes | 6 (0) | 26 (5.2) | 32 (0.1) | 0.000 |
| No | 48,288 (100) | 472 (94.5) | 48,760 (99.9) | |
| Dental care | ||||
| Yes | 4,999 (10.4) | 169 (33.9) | 5,168 (10.6) | 0.000 |
| No | 43,295 (89.6) | 329 (66.1) | 43,624 (89.4) | |
| Surgical operation | ||||
| Yes | 101 (0.2) | 43 (8.6) | 144 (0.3) | 0.000 |
| No | 48,193 (99.8) | 455 (91.4) | 48,648 (99.7) | |
| Family history of HCV | ||||
| Yes | 10,711 (22.2) | 157 (31.5) | 10,868 (22.3) | 0.000 |
| No | 37,583 (77.8) | 341 (68.5) | 37,924 (77.7) | |
| Diabetes mellitus (on insulin) | ||||
| Yes | 61 (0.1) | 38 (7.6) | 99 (0.2) | 0.000 |
| No | 48,233 (99.9) | 460 (92.4) | 48,693 (99.8) | |
Anti-HCV in relation to the place of origin and place of residence
| Anti-HCV | Lower Egypt, n=47,344 (97%) | Upper Egypt, n=1,448 (3%) | Rural, n=20,057 (41.1%) | Urban, n=28,735 (58.9%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Male, n=21,365 (45.1%) | Female, n=25,979 (54.9%) | Male, n=6 (0.4%) | Female, n=1,442 (99.6 %) | Male, n=10,937 (54.5%) | Female, n=9,120 (45.5%) | Male, n=10,434 (36.3%) | Female, n=18,301 (63.7%) | |||
| Positive | 188 (0.9%) | 297 (1.1%) | 6 (100%) | 7 (0.5%) | 0.637 | 124 (1.1%) | 186 (2%) | 70 (0.7%) | 118 (0.6%) | 0.000 |
| Negative | 21,177 (99.1%) | 25,682 (98.9%) | 0 (0%) | 1,435 (99.5%) | 10,813 (98.9%) | 8,934 (98%) | 10,364 (99.3%) | 18,183 (99.4%) | ||
| 0.005 | 0.000 | 0.000 | 0.792 | |||||||
HCV RNA-positive in relation to the place of origin and place of residence
| HCV RNA | Lower Egypt, n=47,344 (97%) | Upper Egypt, n=1,448 (3%) | Rural, n=20,057 (41.1%) | Urban, n=28,735 (58.9%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Male, n=21,365 | Female, n=25,979 | Male, n=6 | Female, n=1,442 | Male, n=10,937 (54.5 %) | Female, n=9,120 (45.5%) | Male, n=10,434 (36.3%) | Female, n=18,301 (63.7%) | |||
| Positive | 145 (0.7%) | 206 (0.8%) | 2 (33.3%) | 2 (0.1%) | 0.040 | 91 (0.8%) | 131 (1.4%) | 56 (0.5%) | 77 (0.4%) | 0.000 |
| Negative | 21,220 (99.3%) | 25,773 (99.2%) | 4 (66.7%) | 1,440 (99.9%) | 10,846 (99.2%) | 8,989 (98.6%) | 10,378 (99.5%) | 18,224 (99.6%) | ||
| 0.149 | 0.000 | 0.000 | 0.164 | |||||||